Astegolimab has demonstrated the potential to reduce the annualized asthma exacerbation rate by up to 43% (140).Anti-IL-25 antibody significantly reduced serum IgE, IL-5, and IL-13 production, eosinophil infiltration (141); abrogated airway smooth muscle hyperplasia; prevented AHR in OVA and HDM induced asthma mouse models (142). Here, IL5 is linked to asthma.